Radiotherapy of incompletely resected, moderately differentiated mast cell tumors in the dog: 37 cases (1989-1993)

Frimberger, Angela E.; Moore, A. S.; LaRue, Susan M.; Gliatto, John M.; Bengtson, A. E.

doi:10.5326/15473317-33-4-320

Cited by 79 publications

(69 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[3][4][5] In this study, a smaller number of well-differentiated and a larger number of intermediate-and poorly differentiated MCT were represented than in previous reports, in which all tumor locations were included. 4,15,22,23 This difference might represent a shift of grading criteria from earlier studies, or it might represent a true influence of location on tumor grade. An earlier study with similar grading criteria reported a distribution of grades comparable to this study when tumors of the trunk and extremities were combined.…”

Section: Discussionmentioning

confidence: 96%

Biologic Behavior and Prognostic Factors for Mast Cell Tumors of the Canine Muzzle: 24 Cases (1990–2001)

Gieger

Théon

Werner

et al. 2003

Veterinary Internal Medicne

View full text Add to dashboard Cite

The medical records of 24 dogs with histologically confirmed mast cell tumors (MCT) of the muzzle were retrospectively evaluated to determine their biologic behavior and prognostic factors. Information on signalment, tumor grade and stage, treatment methods, and pattern of and time to failure and death was obtained from the medical record. Twenty-three dogs were treated with combinations of radiotherapy, surgery, and chemotherapy; 1 dog received no treatment. There were 2 Grade I, 15 Grade II, and 7 Grade III tumors. Tumors were stage 0 (n ϭ 8), stage 1 (5), stage 2 (6), stage 3 (4), and stage 4 (1). Mean and median survival times of treated dogs were 36 and 30 months, respectively. Prognostic factors affecting survival time included tumor grade and presence of metastasis at diagnosis. Dogs with Grade I and II tumors survived longer than dogs with Grade III tumors. Variables, including sex, age, gross versus microscopic disease, and treatment type were not found to affect survival. Local control rate was 75% at 1 year and 50% at 3 years. Tumor grade was the only variable found to affect local control. Dogs with Grade I tumors had longer disease-free intervals than those with Grade II tumors, and dogs with Grade II tumors had longer disease-free intervals than dogs with Grade III tumors. Eight of 9 dogs dying of MCT had local or regional disease progression. Muzzle MCT are biologically aggressive tumors with higher regional metastatic rates than previously reported for MCT in other sites.

show abstract

Section: Discussionmentioning

confidence: 96%

Biologic Behavior and Prognostic Factors for Mast Cell Tumors of the Canine Muzzle: 24 Cases (1990–2001)

Gieger

Théon

Werner

et al. 2003

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Rates of local recurrence with adjuvant radiation therapy have been reported to be 5, 14, and 20%. [21][22][23] Although the rates of local recurrence of studies in which no adjuvant treatments were performed cannot be compared statistically to those in which adjuvant treatments were administered, the rates are not very different and raise the question of the efficacy of adjuvant therapies. Because chemotherapy and especially radiation therapy are associated with considerable morbidity, establishing their efficacy becomes crucial.…”

Section: Discussionmentioning

confidence: 99%

Recurrence Rate, Clinical Outcome, and Cellular Proliferation: Indices as Prognostic Indicators after Incomplete Surgical Excision of Cutaneous Grade II Mast Cell Tumors: 28 Dogs (1994–2002)

Séguin

Besancon

McCallan

et al. 2006

Veterinary Internal Medicne

View full text Add to dashboard Cite

The objectives of this study were to determine local recurrence rate, clinical outcome, and prognostic value of the number of argyrophylic nucleolar organizer regions (AgNORs), presence of proliferating cell nuclear antigen (PCNA), and number of Ki-67-positive nuclei after incomplete surgical excision of canine cutaneous grade II mast cell tumors (MCTs). This retrospective study included 30 MCTs in 28 dogs. Medical records were examined and follow-up information was obtained from owners and referring veterinarians. Only cases in which excision was incomplete and no anvcillary therapy (other than prednisone) for MCT was given were included. Paraffin-embedded tumor tissues were retrieved for AgNORs, PCNA, and Ki-67 staining. Median follow-up time was 811.5 days. Seven (23.3%) tumors recurred locally. Median time to local recurrence was not reached with a mean of 1,713 days. The estimated proportions of tumors that recurred locally at 1, 2, and 5 years were 17.3, 22.1, and 33.3%, respectively. Eleven (39.3%) dogs developed MCTs at other cutaneous locations. Median progressionfree survival was 1,044 days. Median overall survival was 1,426 days. The combination of Ki-67 and PCNA scores was prognostic for local recurrence (P 5 .03) and development of local recurrence was prognostic for decreased overall survival (P 5 .04). Results suggest that a minority of incompletely excised MCTs recur. Therefore, ancillary local therapies may not always be necessary. However, local recurrence can negatively affect survival of the affected dogs. Cellular proliferation indices may indicate the likelihood of MCT recurrence after incomplete excision.

show abstract

“…Also incompletely removed grade 2 MCTs were satisfactory treated by orthovoltage and megavoltage radiation (32). However, some caution is justified since "incomplete surgery" is certainly not always followed by local recurrence (46,77,78 It is striking that in three studies (46,77,78) incompleteness of therapy, defined by the presence of tumour cells in the margins of the surgical specimens, was not always followed by local recurrence.…”

Section: B Radiotherapy Alone or In Combination With Other Therapy Mmentioning

confidence: 99%

“…Radiotherapy has been administered to achieve total control of incompletely removed or locally recurrent MCTs (32,57,101,114).…”

Section: B Radiotherapy Alone or In Combination With Other Therapy Mmentioning

confidence: 99%

Mast cells and canine mast cell tumours. A review

Misdorp

2004

Veterinary Quarterly

103

View full text Add to dashboard Cite

Radiotherapy of incompletely resected, moderately differentiated mast cell tumors in the dog: 37 cases (1989-1993)

Cited by 79 publications

References 0 publications

Biologic Behavior and Prognostic Factors for Mast Cell Tumors of the Canine Muzzle: 24 Cases (1990–2001)

Biologic Behavior and Prognostic Factors for Mast Cell Tumors of the Canine Muzzle: 24 Cases (1990–2001)

Recurrence Rate, Clinical Outcome, and Cellular Proliferation: Indices as Prognostic Indicators after Incomplete Surgical Excision of Cutaneous Grade II Mast Cell Tumors: 28 Dogs (1994–2002)

Mast cells and canine mast cell tumours. A review

Contact Info

Product

Resources

About